Idexx Laboratories Stock Today

IDXX Stock  USD 421.76  0.00  0.00%   

Performance

0 of 100

 
Weak
 
Strong
Very Weak

Odds Of Distress

Less than 1

 
High
 
Low
Very Small
IDEXX Laboratories is trading at 421.76 as of the 28th of November 2024; that is No Change since the beginning of the trading day. The stock's open price was 421.76001. IDEXX Laboratories has a very small chance of experiencing financial distress in the next few years, but has generated negative returns over the last 90 days. Note, on February 14, 2024, Senator Tommy Tuberville of US Senate acquired under $15k worth of IDEXX Laboratories's common stock.
Business Domain
Health Care Equipment & Services
IPO Date
21st of June 1991
Category
Healthcare
Classification
Health Care
IDEXX Laboratories, Inc. develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine. The company has 81.88 M outstanding shares of which 2.08 M shares are currently shorted by private and institutional investors with about 2.06 trading days to cover. More on IDEXX Laboratories

Moving together with IDEXX Stock

  0.77CI Cigna CorpPairCorr
  0.63AHG Akso Health GroupPairCorr

Moving against IDEXX Stock

  0.86WGS GeneDx Holdings CorpPairCorr
  0.85LNSR LENSAR IncPairCorr
  0.82VREX Varex Imaging CorpPairCorr
  0.75VMD Viemed HealthcarePairCorr
  0.72XAIR Beyond AirPairCorr
  0.67CAH Cardinal HealthPairCorr

IDEXX Stock Highlights

ESG Sustainability
Environmental
Governance
Social
CEO PresidentJonathan Mazelsky
Thematic IdeaHealthcare (View all Themes)
Business ConcentrationHealth Care Equipment & Supplies, Health Care Equipment & Services, Health Care, SP 500 Index, NASDAQ Composite, NASDAQ 100 Pre, Nasdaq 100, Healthcare, Health Care, Health Care Equipment & Supplies, Diagnostics & Research, Healthcare (View all Sectors)
Excise Tax ActivitiesAnimal Testing
Average Analyst Recommendation
Financial Strength
Current ValueLast YearChange From Last Year 10 Year Trend
Return On Assets0.270.2592
Sufficiently Up
Slightly volatile
Asset Turnover0.861.123
Way Down
Pretty Stable
Gross Profit Margin0.610.5982
Fairly Up
Slightly volatile
Total Current Liabilities999.1 M951.5 M
Sufficiently Up
Slightly volatile
Total Assets3.4 B3.3 B
Sufficiently Up
Slightly volatile
Total Current Assets1.6 B1.5 B
Sufficiently Up
Slightly volatile
Total Cash From Operating Activities951.8 M906.5 M
Sufficiently Up
Slightly volatile
Debt Levels
IDEXX Laboratories can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand IDEXX Laboratories' financial leverage. It provides some insight into what part of IDEXX Laboratories' total assets is financed by creditors.
Liquidity
IDEXX Laboratories currently holds 1.07 B in liabilities with Debt to Equity (D/E) ratio of 3.28, implying the company greatly relies on financing operations through barrowing. IDEXX Laboratories has a current ratio of 0.87, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about IDEXX Laboratories' use of debt, we should always consider it together with its cash and equity.

Net Income

887.29 Million
IDEXX Laboratories (IDXX) is traded on NASDAQ Exchange in USA. It is located in One IDEXX Drive, Westbrook, ME, United States, 04092 and employs 11,000 people. IDEXX Laboratories is listed under Health Care Equipment & Supplies category by Fama And French industry classification. The company currently falls under 'Large-Cap' category with a current market capitalization of 34.17 B. IDEXX Laboratories conducts business under Health Care Equipment & Supplies sector and is part of Health Care industry. The entity has 81.88 M outstanding shares of which 2.08 M shares are currently shorted by private and institutional investors with about 2.06 trading days to cover. IDEXX Laboratories currently holds about 114.36 M in cash with 906.51 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.37.
Check IDEXX Laboratories Probability Of Bankruptcy
Ownership Allocation
IDEXX Laboratories has a total of 81.88 Million outstanding shares. The majority of IDEXX Laboratories outstanding shares are owned by outside corporations. These institutional investors are usually referred to as non-private investors looking to purchase positions in IDEXX Laboratories to benefit from reduced commissions. Thereupon, third-party entities are subject to a different set of regulations than regular investors in IDEXX Laboratories. Please pay attention to any change in the institutional holdings of IDEXX Laboratories as this could imply that something significant has changed or is about to change at the company. On February 14, 2024, Senator Tommy Tuberville of US Senate acquired under $15k worth of IDEXX Laboratories's common stock.
Check IDEXX Ownership Details

IDEXX Stock Institutional Holders

InstituionRecorded OnShares
Blair William & Co2024-06-30
1.2 M
Brown Advisory Holdings Inc2024-09-30
1.1 M
Norges Bank2024-06-30
994.4 K
Fundsmith Investment Services Ltd.2024-09-30
865 K
Goldman Sachs Group Inc2024-06-30
815.4 K
Legal & General Group Plc2024-06-30
777.3 K
Northern Trust Corp2024-09-30
769.5 K
Jpmorgan Chase & Co2024-06-30
756.2 K
Ubs Asset Mgmt Americas Inc2024-09-30
751.9 K
Vanguard Group Inc2024-09-30
9.7 M
Blackrock Inc2024-06-30
9.6 M
View IDEXX Laboratories Diagnostics

IDEXX Laboratories Historical Income Statement

At this time, IDEXX Laboratories' Income Before Tax is fairly stable compared to the past year. Net Income is likely to rise to about 887.3 M in 2024, despite the fact that Total Other Income Expense Net is likely to grow to (34.2 M). View More Fundamentals

IDEXX Stock Against Markets

IDEXX Laboratories Corporate Executives

Elected by the shareholders, the IDEXX Laboratories' board of directors comprises two types of representatives: IDEXX Laboratories inside directors who are chosen from within the company, and outside directors, selected externally and held independent of IDEXX. The board's role is to monitor IDEXX Laboratories' management team and ensure that shareholders' interests are well served. IDEXX Laboratories' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, IDEXX Laboratories' outside directors are responsible for providing unbiased perspectives on the board's policies.
Brian McKeonCFO, Principal Accounting Officer, Executive VP and TreasurerProfile
Nimrata PESector StrategyProfile
Martin SmithExecutive CTOProfile

Additional Tools for IDEXX Stock Analysis

When running IDEXX Laboratories' price analysis, check to measure IDEXX Laboratories' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy IDEXX Laboratories is operating at the current time. Most of IDEXX Laboratories' value examination focuses on studying past and present price action to predict the probability of IDEXX Laboratories' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move IDEXX Laboratories' price. Additionally, you may evaluate how the addition of IDEXX Laboratories to your portfolios can decrease your overall portfolio volatility.